Drug Profile
Research programme: antiemetic therapeutics - Daewoong Pharmaceutical
Alternative Names: DWJ 1308Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Nausea and vomiting in South Korea